6-K 1 Form6K.txt APPOINTMENT OF LIQUIDATORS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of: August 2012 Commission File Number: 000-51440 China Medical Technologies, Inc (Translation of registrant's name into English) c/o Borrelli Walsh Limited, Level 1, Admiralty Centre, 18 Harcourt Road, Hong Kong (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F:___ Form 40-F:___ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):___ Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):___ Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organised (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other commission filing on EDGAR. Bankruptcy or Receivership China Medical Technologies, Inc (In Liquidation) ("Registrant") announces that an Order was made by the Grand Court of the Cayman Islands ("Cayman Court") on 27 July 2012 ("Order") appointing Cosimo Borrelli of Borrelli Walsh Limited and Kenneth M. Krys of KRyS Global as the Joint Official Liquidators of the Registrant ("Liquidators") as a result of the winding up petition filed with the Cayman Court on 15 June 2012 by the Registrant's creditors. Upon the making of the Order, the powers of the directors of the Registrant ceased and the Liquidators are the only authorised representative of the Registrant. The powers of the Liquidators include, amongst other things, to investigate the affairs of the Registrant and to enter into discussions and negotiations for and on behalf of the Registrant, for the purpose of, but not limited to, restructuring of the Registrant's business and operations and restructuring or rescheduling of the Registrant's indebtedness. An immediate focus of the Liquidators is to gather sufficient information to understand the affairs fo the Registrant and determine whether there is merit in facilitating a restructuring of the Registrant as soon as possible. The Liquidators draw your attention to Section 99 of the Companies of the Companies Law of the Cayman Islands which provides that: "when a winding up order has been made, any disposition of the company's property and any transfer of shares or alteration in the status of the company's members made after the commencement of the winding up is, unless the Court otherwise orders, void." Further, Section 100 of the Companies Law of the Cayman Islands provides that: "(1) If before the presentation for the winding up of a company by the Court- (a) a resolution has been passed by the company for voluntary winding up; (b) the period, if any, fixed for the duration of the company by the articles of association has expired; or (c) the event upon the occurrence of which it is provided by the articles of association that the company is to be wound up has occurred, the winding up of the company is deemed to have commenced at the time of passing of the resolution or the expiry of the relevant period or the occurrence of the relevant event. (2) In any other circumstance not specified in subsection (1), the winding up of a company by the Court is deemed to commence at the time of the presentation of the petition for winding up." Accordingly, any transfer of shares after the filing of the petition on 15 June 2012 is void unless the Cayman Court otherwise orders. The Liquidators have requested the United States Securities and Exchange Commission to suspend the trading in the Registrant's shares immediately. Appropriate announcement will be made as and when there are further developments. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorised. China Medical Technologies, Inc (Registrant) Date: 3 August 2012 By Cosimo Borrelli Joint Official Liquidator China Medical Technologies, Inc (In Liquidation) OMB Number: 3235-0116 Persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1815 (04-09)

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of December, 2011

Commission File Number: 000-51440

CHINA MEDICAL TECHNOLOGIES, INC.

(Translation of registrant’s name into English)

No. 24 Yong Chang North Road

Beijing Economic-Technological Development Area

Beijing 100176

People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨ No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- N/A

CHINA MEDICAL TECHNOLOGIES, INC.

Form 6-K

TABLE OF CONTENTS

	Page
Signature		3
Exhibit 99.1 – Press Release		4

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CHINA MEDICAL TECHNOLOGIES, INC. By: /s/ Takyung (Sam) Tsang Name: Takyung (Sam) Tsang Title: Chief Financial Officer

Date: December 14, 2011

Exhibit 99.1

China Medical Technologies Intends to Implement Debt Restructuring

Beijing, China, December 13, 2011 - China Medical Technologies, Inc. (the “Company”) (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic (“IVD”) company, today announced that the Company intends to implement a debt restructuring plan to improve its balance sheet. The plan may include, without limitation, a debt-for-debt exchange with existing holders of the Company’s convertible notes maturing in August 2013 and December 2016, which may potentially involve holders receiving new debts with different interest rates, maturities and principal amounts compared to the existing debts or other alternatives to be agreed. Holders of the Company’s convertible notes are requested to contact the Company’s Cayman legal representative, Thorp Alberga at cmednoteholders@thorpalberga.com, which will collect contact information from such holders to facilitate their communication with each other to form a noteholders’ committee to liaise with the Company.

This release shall not constitute an offer to sell, or a solicitation of an offer to buy, any securities in any jurisdiction.

About China Medical Technologies, Inc.

China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, including: there can be no assurance that any plan, if pursued, will be successful. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contact

Email: cmednoteholders@thorpalberga.com

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Filing Compare · China Medical Technologies, Inc.